id	等位基因	注释文本
1198	*6	Patients with the CYP2D6*6 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.
1197	*5	Patients with the CYP2D6*5 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.
1196	*4	Patients with the CYP2D6*4 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.
1195	*3	Patients with the CYP2D6*3 allele in combination with another no function allele may have a decreased clearance of mirtazapine as compared to patients with the two normal function alleles. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.
1194	*1xN	Patients carrying the CYP2D6*1xN allele in combination with a normal function may have an increased clearance of mirtazapine as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.
1193	*1	Patients carrying the CYP2D6*1 allele in combination with another normal function allele may have an increased clearance of mirtazapine as compared to patients with two no function alleles and a decreased clearance of mirtazapine as compared to patients with an increased function allele in combination with a normal function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence metabolism of mirtazapine. This annotation only covers the pharmacokinetic relationship between CYP2D6 and mirtazapine and does not include evidence about clinical outcomes.

id	证据的ID	总结
4134	1183618857	CYP2D6 4 + 5 are associated with increased serum concentrations of S(+)-mirtazapine, mirtazapine S(+)/R(-) ratios and S(+)-N-desmethylmirtazapine when treated with mirtazapine in people with Mental Disorders as compared to CYP2D6 1/1.
4133	1183619103	CYP2D6 4/4 is not associated with differences in AUC of desmethylmirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4132	1183619088	CYP2D6 1/1xN is not associated with differences in AUC of desmethylmirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4131	1183619060	CYP2D6 1/1xN is associated with increased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4130	1183619051	CYP2D6 4/4 is associated with decreased total clearance of racemic mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4129	1183619012	CYP2D6 4/4 is not associated with differences in desmethyl-mirtazapine parameters when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4128	1183618996	CYP2D6 1/1xN is associated with increased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4127	1183618967	CYP2D6 4/4 is associated with decreased clearance of S(+) mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4126	1183618807	CYP2D6 4/4 + 4/6 is associated with increased dose/weight adjusted AUC for mirtazapine when exposed to mirtazapine in healthy individuals as compared to CYP2D6 1/1.
4125	1183618754	CYP2D6 3/4 + 4/6 are associated with increased S-mirtazapine plasma levels in non-smokers at day 14 of treatment when treated with mirtazapine in people with Depression as compared to CYP2D6 1/1.

id	类型	评论
579	Update	Added sentence about DPWG 'no recommendation' to phenotype descriptions
578	Update	CA score added as part of scoring system release. LOE assigned following curator review.
577	Update	Minor edits to phenotype descriptions
576	Update	only includes PK evidence
575	Update	Updated OMB race to appropriate biogeographical group

最新招商产品更多>>